Duality Biotherapeutics Details Board and Committee Structure

Duality Biotherapeutics, Inc. ( (HK:9606) ) has provided an update.

Duality Biotherapeutics, Inc. has outlined the current composition of its board of directors, led by chairman and chief executive officer Dr. Zhu Zhongyuan and supported by a mix of executive, non-executive, and independent non-executive directors. The company also detailed the membership and leadership of its three key board committees—Audit, Remuneration, and Nomination—clarifying oversight responsibilities and reinforcing its corporate governance framework for shareholders and market participants.

Independent director Mr. Xie Dong chairs the Audit Committee, while independent director Ms. Chuai Shuyin leads both the Nomination Committee and serves as a member of the Remuneration Committee, alongside other committee members drawn from the board. This structure underscores Duality Biotherapeutics’ alignment with Hong Kong listing governance standards, aiming to enhance transparency, accountability, and investor confidence as it operates in the competitive biotherapeutics industry.

The most recent analyst rating on (HK:9606) stock is a Buy with a HK$493.00 price target. To see the full list of analyst forecasts on Duality Biotherapeutics, Inc. stock, see the HK:9606 Stock Forecast page.

More about Duality Biotherapeutics, Inc.

Duality Biotherapeutics, Inc., incorporated in the Cayman Islands and listed in Hong Kong, operates in the biotherapeutics sector. The company is governed by a board comprising executive, non-executive, and independent non-executive directors, reflecting a typical governance structure for a publicly traded biopharmaceutical firm seeking to balance management oversight with independent supervision.

Average Trading Volume: 736,438

Technical Sentiment Signal: Strong Sell

Current Market Cap: HK$25.26B

See more insights into 9606 stock on TipRanks’ Stock Analysis page.